Has Sophia Yuan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $841 in general payments to Sophia Yuan, MD across 45 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sophia Yuan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sophia Yuan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sophia Yuan, MD

Psychiatry · Clemmons, NCNPI 1700152915

Payments from drug & device makers

$841in general payments, 2019–2025

Across 45 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$404
Johnson & Johnson$83
Lundbeck LLC$81
AstraZeneca$66
Neos Therapeutics, LP$38
Neurocrine Biosciences, Inc.$37
plus $132 from 5 others

What the payments were for

Food & beverage$841100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	22	$404
Johnson & Johnson	5	$83
Lundbeck LLC	5	$81
AstraZeneca	1	$66
Neos Therapeutics, LP	2	$38
Neurocrine Biosciences, Inc.	2	$37
Otsuka America Pharmaceutical, Inc.	2	$37
Avanir Pharmaceuticals, Inc.	2	$33
Indivior Inc.	2	$29
Gilead	1	$18
Neuronetics, Inc.	1	$15

How this compares

$841 in reported general payments places this provider in the 70th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina →

Medicare billing

Part B allowed, 2024

$2,858

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Aripiprazole	16	$482
Duloxetine Hcl	13	$480
Mirtazapine	36	$342
Quetiapine Fumarate	16	$250
Clonazepam	27	$186
Trazodone Hcl	21	$183
Venlafaxine Hcl ErVenlafaxine Hcl	13	$143
Zolpidem Tartrate	19	$127
Fluoxetine Hcl	16	$118
Alprazolam	26	$117
Lamotrigine	11	$81
Lorazepam	15	$51

Paid to pharmacies, not to this prescriber.

Other psychiatry in Clemmons

Craig ChepkeHuntersville$4.1M
James BarkerHickory$4.1M
Mark ReynoldsDurham$3.2M
Oleg TcheremissineCharlotte$2M
Richard WeislerRaleigh$1.2M
Dan BlazerDurham$1M
Samantha Meltzer-BrodyChapel Hill$909K
Andrew KrystalDurham$754K
Brian FarahWinston Salem$605K
Krishna TalluriMorrisville$591K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →